Should access to GLP-1 weight-loss drugs be publicly reimbursed?
14 votes|10 arguments|0 source
Polling consistently shows a majority of citizens support moving forward — democratic legitimacy is on this side. @@yes_4
Pooled safety data from national registries covering ~600 million doses across Europe, North America and Israel.
Systematic review of semaglutide and tirzepatide trials and a cost-effectiveness model for public reimbursement.
Estimation annuelle de la mortalité attribuable aux particules fines (PM2.5) à l'échelle des aires urbaines.